COTY vs IPAR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: COTY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COTY and IPAR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COTY and IPAR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Coty Inc is one of the world's largest beauty companies, operating through two reporting segments. Prestige, which makes up roughly two thirds of sales, is anchored by licensed luxury fragrances (Gucci, Burberry, Hugo Boss, Calvin Klein, Davidoff, Marc Jacobs, Chloe) plus owned or licensed makeup lines such as Kylie Cosmetics. Consumer Beauty covers mass-market cosmetics and skincare, including CoverGirl, Max Factor, Rimmel, Sally Hansen and Bourjois. The company was assembled largely through acquisitions, notably the 2016 purchase of Procter & Gamble beauty brands, which left it carrying a heavy debt load. Investment firm JAB remains the controlling shareholder with a majority stake, and Coty added a dual listing on the Paris Stock Exchange to broaden its investor base.

Full COTY guide

Interparfums creates, manufactures and distributes prestige fragrances under licence from brand owners. It signs a multi-year agreement with a fashion or jewellery house, pays that house a royalty of roughly 6% to 11% of net sales, and takes on everything else: the juice, the bottle, the positioning, the advertising and the distribution into more than 120 countries. The business runs in two segments. European based operations sit inside Interparfums SA, a separately listed Paris subsidiary that Interparfums owns 72% of, and carry Jimmy Choo, Coach, Montblanc, Lacoste, Boucheron, Kate Spade, Karl Lagerfeld, Moncler and Van Cleef & Arpels; that side was about 68% of 2025 net sales. United States based operations carry GUESS, Donna Karan/DKNY, Ferragamo, Abercrombie & Fitch, Hollister, MCM, Roberto Cavalli, Graff, Oscar de la Renta and Anna Sui. A handful of brands are owned outright rather than licensed, including Rochas, Lanvin, Off-White, Goutal and the in-house Solférino line.

Full IPAR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COTY drivers: Prestige fragrance as the growth engine; Balance sheet repair and deleveraging.
• IPAR drivers: The licence book runs long where the revenue is; A staggered pipeline of new names.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The biggest risk is execution: Coty is mid-turnaround with declining like-for-like revenue, weak US prestige fragrance market share, and a Consumer Beauty business that took a large non-cash impairment. For IPAR, the structural risk is that Interparfums does not own most of what it sells, and a licensor can decline to renew or take fragrance in-house, as Alfred Dunhill did when that agreement lapsed on September 30, 2023 without renewal.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COTY if you believe its drivers more; IPAR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COTY and IPAR guides.

COTY. These figures are approximate and describe direction rather than precise values, and they can change quickly around a turnaround. Coty's results shift with fragrance demand, promotional intensity, currency and the pace of its strategic review. Reported numbers have been distorted by one-time items such as the Wella disposal loss and the Consumer Beauty impairment, so headline EPS and margins can differ a lot from adjusted figures. Always verify the latest quarterly release, balance sheet and any updated guidance from primary sources before making a decision.

IPAR. The multiple sits close to the broad market even though the earnings line is guided down this year, which tells you the market is pricing the 2027 and 2028 launch slate rather than the current run rate. Three brokers cut the stock to a hold rating in August 2026 on exactly that reasoning, arguing the pipeline was already in the price. Royalty expense of ~$121.7 million in 2025, about 8.2% of sales, is the recurring cost of the licensing model and rises with brand mix rather than with volume alone.

Headline figures (approximate, Jul 2026): COTY shows segments Prestige (~2/3 of sales, mostly fragrance) and Consumer Beauty (mass makeup/skincare), revenue trend Declining on a like-for-like basis through fiscal 2026, profitability Pressured; took a large non-cash Consumer Beauty impairment and posted a reported quarterly loss, debt / leverage Reduced sharply after the Wella sale to a near-decade low, but still meaningful; IPAR shows revenue (ttm) ~$1.50B, up ~3% year over year, diluted eps (ttm) ~$5.23, against 2026 guidance of ~$4.85, operating margin (h1 2026) ~17.9%, down from ~20.0% a year earlier, net cash ~$65M (~$211M cash and short-term investments against ~$146M of debt).

COTY and IPAR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COTY and IPAR exposure against your real portfolio. It is not an investment adviser.